Antibiotic Legislation Offers Big GAIN For Small Firm: Rib-X Extends Delafloxacin Exclusivity
This article was originally published in The Pink Sheet Daily
Executive Summary
Rib-X is among the first to take advantage of the Generating Antibiotic Incentives Now provisions of the FDA reauthorization legislation with five years’ extra exclusivity for its lead broad spectrum antibiotic candidate, a next-generation fluoroquinolone. Designation for the program came swiftly, company says.
You may also be interested in...
Antibiotic Exclusivity: Which Vision Will GAIN Upper Hand In FDA List-making?
Industry presenters tell FDA a broad list of potential diseases will attract more developer interest, but advocacy groups push for more targeted criteria during a public hearing on the new exclusivity incentive.
Without an IPO, Rib-X Raises $67.5 Million In Venture Funding
Rib-X will use the venture infusion to try to replicate Phase IIb data that indicated superiority to vancomycin for its broad-spectrum fluoroquinolone antibiotic.
GAIN Hearing Will Help FDA Set Pathogen List
The agency is seeking comments on the criteria prescribed in FDASIA and suggestions for other standards necessary to create a list of pathogens that qualified infectious disease products should target.